Canaccord Genuity Analysts Give Cryolife (NYSE:CRY) a $35.00 Price Target

Canaccord Genuity set a $35.00 target price on Cryolife (NYSE:CRY) in a research note released on Wednesday morning, TipRanks reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

A number of other equities analysts have also weighed in on the stock. TheStreet lowered shares of Cryolife from a b- rating to a c+ rating in a report on Wednesday, May 22nd. Zacks Investment Research upgraded shares of Cryolife from a sell rating to a hold rating in a report on Tuesday, April 23rd. Needham & Company LLC restated a hold rating on shares of Cryolife in a report on Sunday, May 12th. Finally, ValuEngine lowered shares of Cryolife from a strong-buy rating to a buy rating in a report on Wednesday, May 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $31.91.

NYSE CRY traded down $0.71 during mid-day trading on Wednesday, reaching $28.31. The stock had a trading volume of 254,265 shares, compared to its average volume of 136,304. Cryolife has a 1 year low of $23.99 and a 1 year high of $36.05. The firm has a market cap of $1.08 billion, a PE ratio of 108.88 and a beta of 0.62. The business’s fifty day moving average price is $29.97. The company has a current ratio of 5.03, a quick ratio of 3.69 and a debt-to-equity ratio of 0.86.

Cryolife (NYSE:CRY) last announced its quarterly earnings data on Tuesday, July 30th. The medical equipment provider reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.03. Cryolife had a net margin of 0.87% and a return on equity of 3.85%. The company had revenue of $71.14 million during the quarter, compared to analyst estimates of $70.79 million. During the same period in the previous year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, research analysts expect that Cryolife will post 0.29 earnings per share for the current year.

In other Cryolife news, VP Scott B. Capps sold 2,000 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $28.55, for a total transaction of $57,100.00. Following the completion of the sale, the vice president now directly owns 141,079 shares in the company, valued at approximately $4,027,805.45. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ronald D. Mccall sold 3,700 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $28.74, for a total transaction of $106,338.00. Following the sale, the director now owns 139,162 shares of the company’s stock, valued at $3,999,515.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,354 shares of company stock valued at $440,366. 4.40% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in CRY. Wasatch Advisors Inc. raised its stake in Cryolife by 50.9% during the 1st quarter. Wasatch Advisors Inc. now owns 498,176 shares of the medical equipment provider’s stock valued at $14,532,000 after buying an additional 168,125 shares during the last quarter. William Blair Investment Management LLC raised its stake in Cryolife by 41.5% during the 1st quarter. William Blair Investment Management LLC now owns 533,110 shares of the medical equipment provider’s stock valued at $15,551,000 after buying an additional 156,485 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in Cryolife during the 1st quarter valued at $3,779,000. Royce & Associates LP raised its stake in Cryolife by 34.4% during the 1st quarter. Royce & Associates LP now owns 371,417 shares of the medical equipment provider’s stock valued at $10,834,000 after buying an additional 95,109 shares during the last quarter. Finally, SG Capital Management LLC purchased a new stake in Cryolife during the 1st quarter valued at $2,227,000. Institutional investors and hedge funds own 71.10% of the company’s stock.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Recommended Story: How is a price target determined?

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.